The benefit of the RALA peptide-based drug delivery system lays in its 30-amino-acid sequence, which condenses anionic cargo-irrespective of size-into nanoparticles that are highly efficient at cellular entry and are able to outperform currently available technologies, according to a company press release. This behavior evades detection and allows for the generation of a potent antigen-specific CD8+ T-cell response. Operating with its RALA platform, pHion can deliver anionic molecules such as mRNA and self-amplifying RNA in a stealth-like way. pHion’s pipeline also includes differentiated therapeutic vaccines for the treatment of ovarian (PTX_V5) and prostate (PTX_V3) cancers. PTX_V1 is a first-in-class therapeutic vaccine in development for treating human papilloma virus-related cancers. One of the first priorities will be the advancement of PTX_V1, pHion’s lead project, into clinical trials in the first half of 2024. The investment will support growth of pHion’s proprietary RALA platform. The investment is meant to further develop next-generation messenger RNA (mRNA) vaccines. InvoX Pharma, a UK-based wholly owned subsidiary of China-based Sino Biopharmaceutical, announced on Jthe completion of a second tranche of investment in pHion Therapeutics, a UK-based vaccine development company.

Sequence of mrna